1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Primary Sclerosing Cholangitis - Pipeline Review, H1 2017

Primary Sclerosing Cholangitis - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 85 pages

Primary Sclerosing Cholangitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis – Pipeline Review, H1 2017, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 2 and 5 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Primary Sclerosing Cholangitis - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
Allergan Plc
Biotie Therapies Corp
ChemoCentryx Inc
Dr. Falk Pharma GmbH
Genextra Spa
Gilead Sciences Inc
iCo Therapeutics Inc.
Iltoo Pharma
NGM Biopharmaceuticals Inc
Sancilio and Company Inc
Shire Plc
Takeda Pharmaceutical Company Ltd
Primary Sclerosing Cholangitis - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
berberine ursodeoxycholate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
bertilimumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
CCX-507 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SC-404 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Stem Cell Therapy for Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
timolumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Featured News and Press Releases
Jan 05, 2017: Phenex Receives $100 Million Milestone Payment From Gilead
Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States
Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases
Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers
Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis
Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting
Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis
Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP
Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding
Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food and Drug Administration for LUM001 in Four Rare Liver Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Biotie Therapies Corp, H1 2017
Primary Sclerosing Cholangitis - Pipeline by ChemoCentryx Inc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Genextra Spa, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by iCo Therapeutics Inc., H1 2017
Primary Sclerosing Cholangitis - Pipeline by Iltoo Pharma, H1 2017
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Sancilio and Company Inc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H1 2017
Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Primary Sclerosing Cholangitis - Dormant Projects, H1 2017
Primary Sclerosing Cholangitis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dermatology Therapeutics Drug Development Pipeline Review, 2016

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Dermatology Therapeutics Drug Development Pipeline Review, 2016 Summary Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population ...

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Potassium Voltage Gated Channel ...

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.